Evidence map›Paper›PMID 32635214›Full record

ReviewPharmaceutics2020

3D Printed Drug Delivery Systems Based on Natural Products.

Ángela Aguilar-de-Leyva, Vicente Linares, Marta Casas, Isidoro Caraballo

Abstract readReview
In one paragraph

Review in Pharmaceutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. New Frontiers in 3D Printing Using Biocompatible Polymers.International journal of molecular sciences · 2025
    Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Trials and Tribulations of MicroRNA Therapeutics.International journal of molecular sciences · 2024
    Review
  13. Review
  14. Review
  15. Biopolymers in Drug and Gene Delivery Systems 2.0.International journal of molecular sciences · 2023
    Article
  16. Article
  17. Review
  18. Polysaccharide-based biomaterials in a journey from 3D to 4D printing.Bioengineering & translational medicine · 2023
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ángela Aguilar-de-LeyvaDepartment of Pharmacy and Pharmaceutical Technology, University of Seville, 41012 Seville, Spain.
Vicente LinaresDepartment of Pharmacy and Pharmaceutical Technology, University of Seville, 41012 Seville, Spain.ORCID 0000-0002-3565-9839
Marta CasasDepartment of Pharmacy and Pharmaceutical Technology, University of Seville, 41012 Seville, Spain.ORCID 0000-0002-3439-9094
Isidoro CaraballoDepartment of Pharmacy and Pharmaceutical Technology, University of Seville, 41012 Seville, Spain.ORCID 0000-0003-1905-7755

Funding

Ministerio de Ciencia, Innovación y Universidades of Spain RTI2018-095041-B-C31
6 · The paper itself

Abstract

In the last few years, the employment of 3D printing technologies in the manufacture of drug delivery systems has increased, due to the advantages that they offer for personalized medicine. Thus, the possibility of producing sophisticated and tailor-made structures loaded with drugs intended for tissue engineering and optimizing the drug dose is particularly interesting in the case of pediatric and geriatric population. Natural products provide a wide range of advantages for their application as pharmaceutical excipients, as well as in scaffolds purposed for tissue engineering prepared by 3D printing technologies. The ability of biopolymers to form hydrogels is exploited in pressure assisted microsyringe and inkjet techniques, resulting in suitable porous matrices for the printing of living cells, as well as thermolabile drugs. In this review, we analyze the 3D printing technologies employed for the preparation of drug delivery systems based on natural products. Moreover, the 3D printed drug delivery systems containing natural products are described, highlighting the advantages offered by these types of excipients.

Indexed as

3D printingbioinksdrug deliverynatural productsprintability

Identifiers

PMID32635214
PMCPMC7407805

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.